Advertisement

Clinical Rheumatology

, 26:1877 | Cite as

IgG deposits can be detected in cell nuclei of patients with both lupus erythematosus and malignancy

  • Ingrid Böhm
Original Article

Abstract

The purpose was to find immunological disturbances in lupus erythematosus (LE) patients with concomitant malignancy. 159 LE patients have been analyzed. Routine laboratory analyses including screening of serum autoantibodies and analyzing peripheral blood mononuclear cells by using flow cytometry have been performed. Malignant diseases have been revealed in 12 (7.5%) cases. All patients suffered from internal malignancies. LE patients with vs without malignancy had significantly decreased anti-double stranded DNA (16.6 vs 31.6%; p < 0.05) and increased anti-SSA/SSB (83.3 vs 32.2%/26.4%; p < 3 × 10−12) antibodies. Patients with neoplastic disease had increased IgG within the cell nuclei (76.6% ± 9.6 vs 51.8 ± 4.6%; p < 2 × 10−7). IgG penetrating living cells has been shown previously in SLE but has so far not been found in association to LE patients with malignant disease.

Keywords

Anti-dsDNA autoantibodies Apoptosis Autoantibodies Cell nucleus Immunoglobulin G (IgG) Lupus erythematosus Neoplasm 

References

  1. 1.
    Sweeney DM, Manzi S, Janosky J et al (1995) Risk of malignancy in women with systemic lupus erythematosus. J Rheumatol 22:1478–1482PubMedGoogle Scholar
  2. 2.
    Abu-Shakra M, Gladman DD, Urowitz MB (1996) Malignancy in systemic lupus erythematosus. Arthritis Rheum 39:1050–1054PubMedCrossRefGoogle Scholar
  3. 3.
    Menon S, Snaith ML, Isenberg DA (1993) The association of malignancy with SLE: an analysis of 150 patients under long-term review. Lupus 2:177–181PubMedGoogle Scholar
  4. 4.
    Lopez Dupla M, Khamashta M, Pintado Garcia V et al (1993) Malignancy in systemic lupus erythematosus: a report of five cases in a series of 96 patients. Lupus 2:377–380PubMedGoogle Scholar
  5. 5.
    Nived O, Bengtsson A, Johnsen A et al (2001) Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 10:500–504PubMedCrossRefGoogle Scholar
  6. 6.
    Keith WD, Kelly AP, Sumrall AJ et al (1980) Squamous cell carcinoma arising in lesions of discoid lupus erythematosus in black persons. Arch Dermatol 116:315–317PubMedCrossRefGoogle Scholar
  7. 7.
    Millard G, Barker DG (1978) Development of squamous cell carcinoma in chronic discoid lupus erythematosus. Clin Exp Dermatol 3:161–166PubMedCrossRefGoogle Scholar
  8. 8.
    Miyagawa S, Minowa R, Yamashina Y et al (1996) Development of squamous cell carcinoma in chronic discoid lupus erythematosus: a report of two patients with anti-Ro/SSA antibodies. Lupus 5:630–632PubMedGoogle Scholar
  9. 9.
    Ehrenfeld M, Shoenfeld Y (2001) Malignancies and autoimmune rheumatic diseases. J Clin Rheumatol 7:47–50PubMedCrossRefGoogle Scholar
  10. 10.
    Ashok BT, Ali R (1998) Binding of human anti-DNA autoantibodies to reactive oxygen species modified-DNA and probing oxidative DNA damage in cancer using monoclonal antibody. Int J Cancer 78:404–409PubMedCrossRefGoogle Scholar
  11. 11.
    Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRefGoogle Scholar
  12. 12.
    Zhan X, Hu X, Friedman S et al (1992) Analysis of endogenous and exogenous nuclear translocation of fibroblast growth factor-1 in NIH 3T3 cells. Biochem Biophys Res Commun 188:982–991PubMedCrossRefGoogle Scholar
  13. 13.
    Castanet J, Taillan B, Lacour JP et al (1995) Subacute cutaneous lupus erythematosus associated with Hodgkin’s disease. Clin Rheumatol 14:692–694PubMedCrossRefGoogle Scholar
  14. 14.
    Schewach-Millet M, Shapiro D, Ziv R et al (1988) Subacute cutaneous lupus erythematosus associated with breast carcinoma. J Am Acad Dermatol 19:406–408PubMedCrossRefGoogle Scholar
  15. 15.
    Blanc D, Kienzler JL (1982) Lupus erythematosus gyratus repens. Report of a case associated with lung carcinoma. Clin Exp Dermatol 7:129–134PubMedCrossRefGoogle Scholar
  16. 16.
    Neumann R, Schmidt JB, Niebaur G (1986) Subacute cutaneous lupus erythematosus-like gyrate erythema. Report of a case associated with a breast cancer. Dermatologica 173:146–149PubMedCrossRefGoogle Scholar
  17. 17.
    Hofmann A, Hofmann B, Sollberg S (1995) Chilblainlupus assoziiert mit akuter myelomonozytärer Leukämie (FAB M4). Z Hautkr 70:350–354Google Scholar
  18. 18.
    Sulkes A, Naparstek Y (1991) The infrequent association of systemic lupus erythematosus and solid tumors. Cancer 6:1389–1393CrossRefGoogle Scholar
  19. 19.
    Bhalla R, Ajmani HS, Kim WW et al (1993) Systemic lupus erythematosus and Hodgkin’s lymphoma. J Rheumatol 20:1316–1320PubMedGoogle Scholar
  20. 20.
    Munzert G, Frickhofen N, Bauditz J et al (1997) Concomitant manifestation of systemic lupus erythematosus and low-grade non-Hodgkin’s lymphoma. Leukemia 11:1324–1328PubMedCrossRefGoogle Scholar
  21. 21.
    Lv S, Zhang J, Wu J et al (2005) Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice. Immunol Lett 99:217–227PubMedCrossRefGoogle Scholar
  22. 22.
    Alarcon-Segovia D, Ruiz-Arguelles A, Fishbein E (1979) Antibody penetration into living cells. I. Intranuclear immunoglobulin in peripheral blood mononuclear cells in mixed connective tissue disease and systemic lupus erythematosus. Clin Exp Immunol 35:364–375PubMedGoogle Scholar
  23. 23.
    Portales-Perez D, Alarcon-Segovia D, Llorente L et al (1998) Penetrating anti-DNA monoclonal antibodies induce activation of human peripheral blood mononuclear cells. J Autoimmun 11:563–571PubMedCrossRefGoogle Scholar
  24. 24.
    Ruiz-Arguelles A, Rivadeneyra-Espinoza L, Alarcon-Segovia D (2003) Antibody penetration into living cells: pathogenic, preventive and immuno-therapeutic implications. Curr Pharm Des 9:1881–1887PubMedCrossRefGoogle Scholar
  25. 25.
    Böhm I (2003) Disruption of the cytoskeleton after apoptosis induction with autoantibodies. Autoimmunity 36:183–189PubMedCrossRefGoogle Scholar
  26. 26.
    Böhm I (2004) Apoptosis: the link between autoantibodies and leuko-/lymphocytopenia in patients with lupus erythematosus. Scand J Rheumatol 33:409–416PubMedCrossRefGoogle Scholar
  27. 27.
    Kozyr AV, Sashchenko LP, Kolesnikov AV et al (2002) Anti-DNA autoantibodies reveal toxicity to tumor cell lines. Immunol Lett 80:41–47PubMedCrossRefGoogle Scholar
  28. 28.
    Syrigos KN, Charalambopoulos A, Pliarchopoulou K et al (2000) The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res 20:4351–4353PubMedGoogle Scholar
  29. 29.
    Blaes F, Klotz M, Huwer H et al (2000) Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann Thorac Surg 69:254–258PubMedCrossRefGoogle Scholar
  30. 30.
    Casciola-Rosen LA, Anhalt G, Rosen A (1994) Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179:1317–1330PubMedCrossRefGoogle Scholar
  31. 31.
    Ayukawa K, Taniguchi S, Masumoto J et al (2000) La autoantigen is cleaved in the COOH terminus and loses the nuclear localization signal during apoptosis. J Biol Chem 275:34465–34470PubMedCrossRefGoogle Scholar
  32. 32.
    George J, Blank M, Levy Y et al (1998) Differential effects of anti-beta-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 97:900–906PubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2007

Authors and Affiliations

  1. 1.Department of RadiologyUniversity of BonnBonnGermany

Personalised recommendations